Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Blood Adv. 2023 Nov 14;7(21):6762-6766. doi: 10.1182/bloodadvances.2023010742.

Authors

Alessandro Broccoli^{1

2}, Lisa Argnani², Laura Nanni^{1

2}, Vittorio Stefoni^{1

2}, Cinzia Pellegrini¹, Beatrice Casadei¹, Gabriele Gugliotta¹, Matteo Carella^{1

2}, Paolo Elia Coppola^{1

2}, Gianmarco Bagnato^{1

2}, Pier Luigi Zinzani^{1

2}

Affiliations

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna, Italy.
² Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Cladribine
Humans
Leukemia, Hairy Cell* / drug therapy
Rituximab / therapeutic use
Salvage Therapy

Substances

Rituximab
Cladribine
Antibodies, Monoclonal